Skip to main content
Retour
Watch Compare

NewAmsterdam Pharma Co N.V.

Qualité des données : 100%
NAMSW
Nasdaq Manufacturing Chemicals
23,50 €
▲ 1,00 € (4,44%)
Cap. Boursière: 2,78 B
Prix
23,50 €
Cap. Boursière
2,78 B
Fourchette du Jour
23,50 € — 23,50 €
Fourchette 52 Semaines
6,30 € — 29,99 €
Volume
2 131
Ouverture 24,41 €
Moyenne 50J / 200J
21,26 €
10,52% above
Moyenne 50J / 200J
19,40 €
21,14% above

Quick Summary

Points Clés

Negative free cash flow of -147,78 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-50,61%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-27,06%
Au-dessus de la moyenne du secteur (-53,47%)
ROIC-23,67%
Net Margin-905,74%
Op. Margin-1002,90%

Sécurité

Debt / Equity
N/A
Current Ratio12,57
Interest CoverageN/A

Valorisation

PE (TTM)
-13,65
En dessous de la moyenne du secteur (-1,47)
P/B Ratio3,82
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -13,7 -1,5
P/B 3,8 1,6
ROE % -27,1 -53,5
Net Margin % -905,7 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -50,61% Revenue Growth (3Y) 26,38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 22,50 M Net Income (TTM) -203,82 M
ROE -27,06% ROA -25,45%
Gross Margin N/A Operating Margin -1002,90%
Net Margin -905,74% Free Cash Flow (TTM) -147,78 M
ROIC -23,67% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 12,57
Interest Coverage N/A Asset Turnover 0,03
Working Capital 674,06 M Tangible Book Value 728,07 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -13,65 Forward P/E N/A
P/B Ratio 3,82 P/S Ratio 123,67
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -5,31%
Market Cap 2,78 B Enterprise Value 2,24 B
Per Share
EPS (Diluted TTM) -1,72 Revenue / Share 0,19
FCF / Share -1,25 OCF / Share -1,25
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 72,51%
SBC-Adj. FCF -201,18 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 22,50 M 45,56 M 14,09 M
Net Income -203,82 M -241,60 M -176,94 M
EPS (Diluted) -1,72 -2,56 -2,15
Gross Profit — — —
Operating Income -225,68 M -176,29 M -182,97 M
EBITDA — — —
R&D Expenses 141,83 M 151,41 M 159,42 M
SG&A Expenses 106,35 M 70,45 M 37,63 M
D&A 220 000,0 113 000,0 49 000,0
Interest Expense — 287 000,0 287 000,0
Income Tax -1 000,0 -1 000,0 27 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 769,28 M 864,62 M 347,10 M
Total Liabilities 85,85 M 107,12 M 58,70 M
Shareholders' Equity 683,43 M 757,50 M 288,39 M
Total Debt — — —
Cash & Equivalents 490,00 M 771,74 M —
Current Assets 675,70 M 863,41 M 346,79 M
Current Liabilities 85,79 M 106,92 M 49,90 M